ECTRIMS 2018: Day 2 Update

11 Oct 2018

Written by Sharon Salt, Editor

Conferences Neurodegeneration and degenerative disease

Video highlight You might also like: ECTRIMS 2018: Day 1 Update Landmark simvastatin trial for secondary progressive multiple sclerosis begins in the UK Ibudilast decreases progression of brain atrophy in progressive multiple sclerosis Ask the Experts: Emerging therapies in multiple sclerosis (Part II: stem cells and future research) Today's news Novel treatments for multiple sclerosis on the horizon Pick of the posters Comi G, Kappos L, Hartung H-P et al. Ozanimod reduces rates of annualized relapse requiring steroids or hospitalization versus interferon B-1a: pooled results from 2 multicenter, randomized, double-blind, Phase III studies in relapsing multiple sclerosis (SUNBEAM and RADIANCE). The authors...